Our data demonstrate for the first time that circ‐CMPK1/miR‐302e/cyclin D1 signaling plays an essential regulatory role in NSCLC and targeting this axis may be an efficacious avenue for treatment of NSCLC patients. Here, CCND1 is linked to non-small cell lung carcinoma.